Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABBR2 | O75899 | 4/20 | 0.50 |
| ▸ | GABBR1 | Q9UBS5 | 4/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | THPO | P40225 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | FDPS | P14324 | 3/20 | 0.40 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PAOX | Q6QHF9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8949817 | 0.98 | GABBR2 (0.48) | GABBR2GABBR1CYP1A2TSHRTHPO | |
| SCHEMBL8949921 | 0.98 | GABBR2 (0.48) | GABBR2GABBR1CYP1A2TSHRTHPO | |
| SCHEMBL8949690 | 0.93 | GABBR2 (0.52) | GABBR2GABBR1CYP1A2TSHRTHPO | |
| Phosphoric Acid SCHEMBL27508186 | 0.85 | LMNA (0.50) | GABBR2GABBR1CYP1A2TSHRTHPO | |
| Phosphoric Acid SCHEMBL28144890 | 0.82 | FDPS (0.48) | GABBR2GABBR1CYP1A2TSHRTHPO | |
| Phosphoric Acid SCHEMBL3918672 | 0.82 | FDPS (0.48) | GABBR2GABBR1CYP1A2TSHRTHPO | |
| SCHEMBL8950061 | 0.81 | GABBR2 (0.56) | GABBR2GABBR1CYP1A2TSHRTHPO | |
| SCHEMBL8949882 | 0.79 | DNM1 (0.59) | GABBR2GABBR1TSHRFDPSGABRR1 | |
| Butylamine SCHEMBL8949981 | 0.78 | GABBR2 (0.58) | GABBR2GABBR1CYP1A2TSHRTHPO | |
| Phosphoric Acid SCHEMBL6535607 | 0.76 | BLM (0.52) | GABBR2GABBR1CYP1A2TSHRTHPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5616560-A | Methods for the treatment of osteoporosis using bisphosphonates and parathyroid hormone | THE PROCTER & GAMBLE COMPANY (US) | 1997-04-01 | — | — | US | claimed |
| EP-0573604-B1 | METHODS FOR THE TREATMENT OF OSTEOPOROSIS | PROCTER & GAMBLE PHARMA (US) | 1995-03-15 | — | — | EP | claimed |
| EP-0573604-A1 | METHODS FOR THE TREATMENT OF OSTEOPOROSIS. | NORWICH EATON PHARMA (US) | 1993-12-15 | — | — | EP | claimed |
| WO-1992014474-A1 | METHODS FOR THE TREATMENT OF OSTEOPOROSIS | NORWICH EATON PHARMACEUTICALS, INC. (US) | 1992-09-03 | — | — | WO | claimed |
| US-6329354-B1 | ADMINISTERING BONE ACTIVE PHOSPHONATE, ADMINISTERING ESTROGEN HORMONE | THE PROCTER & GAMBLE COMPANY | 2001-12-11 | — | — | US | disclosed |
| EP-1158987-A1 | METHODS OF INCREASING BONE VOLUME USING NON-NATURALLY-OCCURRING FP SELECTIVE AGONISTS AND ANTIRESORPTIVE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2001-12-05 | — | — | EP | disclosed |
| WO-2000051617-A1 | METHODS OF INCREASING BONE VOLUME USING NON-NATURALLY-OCCURRING FP SELECTIVE AGONISTS AND ANTIRESORPTIVE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-08 | — | — | WO | disclosed |
| US-5869471-A | Methods for the treatment of arthritis using phosphonates and NSAIDS | THE PROCTOR & GAMBLE COMPANY (US) | 1999-02-09 | — | — | US | disclosed |
| EP-0648120-B1 | USE OF PHOSPHONATES FOR THE TREATMENT OF OSTEOPOROSIS | PROCTER & GAMBLE PHARMA (US) | 1997-12-29 | — | — | EP | disclosed |
| US-5574024-A | Methylene phosphonoalkylphosphinates, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism | EBETINO FRANK H (US) | 1996-11-12 | — | — | US | disclosed |
| EP-0650361-A1 | COMPOSITIONS FOR THE TREATMENT OF ARTHRITIS CONTAINING PHOSPHONATES AND NSAIDS | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1995-05-03 | — | — | EP | disclosed |
| EP-0648120-A1 | USE OF PHOSPHONATES FOR THE TREATMENT OF OSTEOPOROSIS | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1995-04-19 | — | — | EP | disclosed |
| EP-0573604-B1 | METHODS FOR THE TREATMENT OF OSTEOPOROSIS | PROCTER & GAMBLE PHARMA (US) | 1995-03-15 | — | — | EP | disclosed |
| WO-1994000129-A1 | USE OF PHOSPHONATES FOR THE TREATMENT OF OSTEOPOROSIS | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1994-01-06 | — | — | WO | disclosed |
| WO-1994000130-A1 | COMPOSITIONS FOR THE TREATMENT OF ARTHRITIS CONTAINING PHOSPHONATES AND NSAIDS | PROCTER & GAMBLE PHARMACEUTICALS, INC. (US) | 1994-01-06 | — | — | WO | disclosed |
| EP-0298553-B1 | METHYLENE PHOSPHONOALKYLPHOSPHINATES, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR TREATING ABNORMAL CALCIUM AND PHOSPHATE METABOLISM | Norwich Eaton Pharmaceuticals, Inc. (US) | 1992-01-15 | — | — | EP | disclosed |
| EP-0298553-A1 | Methylene phosphonoalkylphosphinates, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism | Norwich Eaton Pharmaceuticals, Inc. (US) | 1989-01-11 | — | — | EP | disclosed |